Prognostic Factors for Wilms Tumor Recurrence: A Review of the Literature
Autor: | Alissa Groenendijk, Rajkumar Venkatramani, Ronald R. de Krijger, Norbert Graf, Jesper Brok, James I. Geller, Marry M. van den Heuvel-Eibrink, Jarno Drost, Annelies M. C. Mavinkurve-Groothuis, Filippo Spreafico, Christian Rübe, J. Godzinski, Daniela Perotti, Harm van Tinteren |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
0301 basic medicine
Oncology Cancer Research Prognostic variable medicine.medical_specialty recurrence Review Loss of heterozygosity 03 medical and health sciences 0302 clinical medicine Internal medicine Overall survival medicine Copy-number variation RC254-282 Treatment regimen business.industry Advanced stage Neoplasms. Tumors. Oncology. Including cancer and carcinogens Wilms tumor Wilms' tumor medicine.disease Tumor recurrence 030104 developmental biology pediatric 030220 oncology & carcinogenesis prognosis business |
Zdroj: | Cancers Cancers, Vol 13, Iss 3142, p 3142 (2021) |
ISSN: | 2072-6694 |
Popis: | Simple Summary A Wilms tumor is a childhood kidney tumor. In high-income countries, 90% of patients with this tumor survive. However, the tumor recurs in 15% of patients. It is important to identify the patients at risk of recurrence in order to adjust treatment in such a way that recurrence may potentially be prevented. However, we are currently unable to determine precisely which patients are at risk of recurrence. Therefore, we present an overview of factors that influence the risk of recurrence, also known as prognostic factors. These factors range from patient-, tumor- and treatment-related characteristics to geographic and socioeconomic factors. In addition to these factors, biological markers, such as genetic alterations, should be studied more intensively as these markers may be able to better identify patients at risk of tumor recurrence. Abstract In high-income countries, the overall survival of children with Wilms tumors (WT) is ~90%. However, overall, 15% of patients experience tumor recurrence. The adverse prognostic factors currently used for risk stratification (advanced stage, high risk histology, and combined loss of heterozygosity at 1p and 16q in chemotherapy-naïve WTs) are present in only one third of these cases, and the significance of these factors is prone to change with advancing knowledge and improved treatment regimens. Therefore, we present a comprehensive, updated overview of the published prognostic variables for WT recurrence, ranging from patient-, tumor- and treatment-related characteristics to geographic and socioeconomic factors. Improved first-line treatment regimens based on clinicopathological characteristics and advancing knowledge on copy number variations unveil the importance of further investigating the significance of biological markers for WT recurrence in international collaborations. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |